IL37560A - 15-methyl prostaglandin a1 and a2 compounds - Google Patents
15-methyl prostaglandin a1 and a2 compoundsInfo
- Publication number
- IL37560A IL37560A IL37560A IL3756071A IL37560A IL 37560 A IL37560 A IL 37560A IL 37560 A IL37560 A IL 37560A IL 3756071 A IL3756071 A IL 3756071A IL 37560 A IL37560 A IL 37560A
- Authority
- IL
- Israel
- Prior art keywords
- pge
- formulμ
- cis
- trans
- neutral
- Prior art date
Links
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 title 1
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 title 1
- 150000003155 prostaglandin A2 derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 230000007935 neutral effect Effects 0.000 claims abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 239000012024 dehydrating agents Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 2
- 150000003180 prostaglandins Chemical class 0.000 abstract 2
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 230000018044 dehydration Effects 0.000 abstract 1
- 238000006297 dehydration reaction Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1314292 Prostaglandins UPJOHN CO 18 Aug 1971 [14 Sept 1970] 38782/71 Heading C2C Novel optically active prostaglandins of the formulµ or racemic compounds of those formulµ and the mirror images thereof, wherein R 1 is H, C 1-8 alkyl, or a pharmacologically acceptable cation, R 2 is CH 3 or CH 3 CH 2 , and X is -CH 2 CH 2 - or trans-CH=CH-, and both Y and Z are -CH 2 -CH 2 -, or X is trans-CH=CH-, Y is cis-CH=CH- and Z is -CH 2 -CH 2 - or cis-CH=CH- are prepared by the neutral dehydration of 15 - methyl - (or 15 - ethyl)- PGE 1 , -PEG 2 , -PGE 3 or -dihydro-PGE 1 or the C 1-8 alkyl esters thereof. Pharmaceutical compositions, suitable for parenteral administration, contain the above novel compounds together with pharmaceutically acceptable carriers. The novel compounds possess hypotensive activity and the ability to reduce and control gastric secretion and increase the flow of blood to mammalian kidney.
[GB1314292A]
Claims (1)
1. Or a o compoun o a ormula and the mirror thereof wherein of one to 8 carbon or a acceptable wherein R2 is methyl and wherein X is and is or and Z is a racemic compound of that formu a and mirror image is hydrogen or of one 8 carbon is X is or and Z which 2 2 2 domprises dehydrating ah optically active compound of the or racemic mirror image A process according to 7 wherein said dehydrating agent a mixture of a oarbodllmlde and a A process according to claim 7 whereto neutral dehydrating agent a mixture of dleyclohexylcarbodllmlde or a racemlc compound that formula and the mirror image wherein hydrogen or of one to 8 carbon wherein R is Y 2 and comprises dehydrating an optically active Compound of the or a raoemio compound of that formula and the mirror image wherein R Z are as defined with neutral dehydrating A process according to claim 13 wherein said neutral dehydrating agent a mixture of a and a copper insufficientOCRQuality
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7210570A | 1970-09-14 | 1970-09-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL37560A0 IL37560A0 (en) | 1971-11-29 |
| IL37560A true IL37560A (en) | 1976-04-30 |
Family
ID=22105603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL37560A IL37560A (en) | 1970-09-14 | 1971-08-24 | 15-methyl prostaglandin a1 and a2 compounds |
Country Status (12)
| Country | Link |
|---|---|
| AU (1) | AU456371B2 (en) |
| BE (1) | BE772584A (en) |
| CA (1) | CA950901A (en) |
| DE (1) | DE2145600A1 (en) |
| ES (1) | ES395036A2 (en) |
| FR (1) | FR2106500B1 (en) |
| GB (1) | GB1314292A (en) |
| IL (1) | IL37560A (en) |
| NL (1) | NL7112466A (en) |
| PH (1) | PH12134A (en) |
| SU (1) | SU399108A3 (en) |
| ZA (1) | ZA715518B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3892795A (en) * | 1971-04-12 | 1975-07-01 | Upjohn Co | 16-Methyl and 16,16 dimethyl PGA{HD 2 {B compounds |
| US3954832A (en) * | 1972-07-24 | 1976-05-04 | The Upjohn Company | 16-And 16,16-methyl and ethyl substituted PGA1 -type compounds |
-
1971
- 1971-08-16 CA CA120,632,A patent/CA950901A/en not_active Expired
- 1971-08-18 GB GB3878271A patent/GB1314292A/en not_active Expired
- 1971-08-18 ZA ZA715518A patent/ZA715518B/en unknown
- 1971-08-24 IL IL37560A patent/IL37560A/en unknown
- 1971-08-25 PH PH12784A patent/PH12134A/en unknown
- 1971-09-10 NL NL7112466A patent/NL7112466A/xx unknown
- 1971-09-13 SU SU1695975A patent/SU399108A3/ru active
- 1971-09-13 DE DE19712145600 patent/DE2145600A1/en active Pending
- 1971-09-13 FR FR7132974A patent/FR2106500B1/fr not_active Expired
- 1971-09-13 AU AU33396/71A patent/AU456371B2/en not_active Expired
- 1971-09-13 ES ES395036A patent/ES395036A2/en not_active Expired
- 1971-09-14 BE BE772584A patent/BE772584A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2106500B1 (en) | 1974-11-15 |
| ES395036A2 (en) | 1973-12-16 |
| AU456371B2 (en) | 1974-12-19 |
| AU3339671A (en) | 1973-03-22 |
| ZA715518B (en) | 1972-05-31 |
| IL37560A0 (en) | 1971-11-29 |
| FR2106500A1 (en) | 1972-05-05 |
| DE2145600A1 (en) | 1972-03-16 |
| PH12134A (en) | 1978-11-07 |
| CA950901A (en) | 1974-07-09 |
| NL7112466A (en) | 1972-03-16 |
| GB1314292A (en) | 1973-04-18 |
| BE772584A (en) | 1972-03-14 |
| SU399108A3 (en) | 1973-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4127725A (en) | Cis-13-PGE1,15-methyl esters | |
| GB1355147A (en) | Oxoprostanoic acid derivatives | |
| US4128713A (en) | 6,7-Didehydro-PGI1 compounds | |
| IL37560A (en) | 15-methyl prostaglandin a1 and a2 compounds | |
| US4281113A (en) | 2,5-Inter-o-phenylene-3,4-dinor-6,9α-epoxy-6.beta.-5-iodo-PGF1 compounds | |
| GB1431414A (en) | Prostanoic acid derivatives | |
| US4065631A (en) | 17-Phenyl-18,19,20-trinor-cis-4,5-didehydro-PGF1β compounds | |
| GB1410853A (en) | Pharmaceutically useful prostaglandin derivatives | |
| GB2037752A (en) | 2,5-inter-o-phenylene-3,4-dinor-pgf and pgi compounds | |
| GB1251750A (en) | ||
| DD201884A5 (en) | PROCESS FOR THE PREPARATION OF CARBACYCLINE DERIVATIVES | |
| US4126744A (en) | 4-Oxo-PGI1 compounds | |
| GB1361863A (en) | Piperazine derivatives their preparation and pharmaceutical compositions containing them | |
| US4130591A (en) | 2-Decarboxy-2-hydroxy-methyl-13,14-didehydro-16-phenoxy PGF compounds | |
| GB1430995A (en) | 13-cis-prostaglandin derivatives and their preparation | |
| US4324889A (en) | 2,5-Inter-o-phenylene-3,4-dinor-6,9α-epoxy-6β-5-iodo-PGF1 amides | |
| US3983163A (en) | 5-Oxa phenyl- and phenoxy-substituted prostaglandin β, analogs | |
| US4289893A (en) | 2,5-Inter-O-phenylene-3,4-dinor-PGF2 compounds | |
| ES418575A1 (en) | Difluoromethylene substituted prostaglandin derivatives | |
| US4010194A (en) | 5-Oxa phenyl- and phenoxy-substituted prostaglandin A1 analogs | |
| US4301294A (en) | 16-Phenoxy PGE2 compounds | |
| US4321370A (en) | 2,5-Inter-o-phenylene-3,4-dinor-6,9α-epoxy-6β-PGF1 compounds | |
| US4301078A (en) | Trans-4,5,13,14-tetradehydro-PGI1 compounds | |
| US4235788A (en) | 6,7-Didehydro- or 7,8-didehydro-PGI1 acyl-substituted phenyl esters | |
| US3968144A (en) | 5-Oxa-11-deoxy phenyl- and phenoxy-substituted prostalandin E1 analogs |